33 results about "Ethylmalonic acid" patented technology

The present invention relates to a pharmaceutical formulation comprising a polypeptide and a buffer selected from the group consisting of diethylmalonic acid, trimellitic acid, shikimic acid, glycinamid, 2-amino-2-methyl-1,3-propanediol (AMPD) and tetraethylammonium (T.E.A.) or salts thereof. Further more the invention relates to a method for improving stability of a polypeptide in a purification process comprising the step of applying a buffer selected from the group consisting of diethylmalonic acid, trimellitic acid, shikimic acid, glycinamid, AMPD and T.E.A. or salts thereof to said purification process.

The invention discloses a biosynthetic gene cluster of phoslactomycins produced by Streptomyces platensis SAM-0654. The whole gene cluster contains twenty twelve genes as follows: seven I-type linear polyketone synthetase (PKS) genes, two ethylmalonyl CoA synthetase genes, four cyclohexylformyl-CoA synthetase genes, six post-modified enzyme genes, two regulation genes and a resistance gene. Through carrying out genetic operation on the biosynthetic gene cluster, the synthesis of the phoslactomycins can be blocked. The gene cluster provided by the invention can be used for output variation of the phoslactomycins, combination generation of polyketone compounds and the like, and also can be used for searching and finding compounds or genes for medicine, industry or agriculture.

The invention discloses a method for preparing high-quality mercaptoacetic acid from a tail solution from O-alkyl-N-alkyl thinocarbamate production. The method comprises the following steps: (1) performing acidizing treatment on the tail solution by using an inorganic acid, and controlling the pH value to be 0.5-1.5; (2) leaving to stand for 6-48 hours, separating suspended organic matters, extracting by using an organic solvent, and extracting by using an extraction agent, thereby obtaining an extraction liquid, wherein the volume ratio of the total amount of the organic solvent to an acidifying liquid is (2.5:0.01)-(2.5:0.1), the organic solvent consists of 40-60wt% of glutaric acid diethyl ester and 40-060wt% of ethyl malonic acid diethyl ester, the volume ratio of the total amount of the extracting agent to a new acidifying liquid is (2:0.1)-(2:2), and the extracting agent is prepared by mixing n-amyl ether, isoamyl ether and sec-butyl methyl ether in a mass ratio of (1-3):(1-3):(1-3); (3) removing the solvent and water from the extraction liquid, thereby obtaining crude acid; (4) performing flash evaporation on the crude acid. The method is high in recycling rate, high in product purity, good in quality and simple in process.

The invention relates to a method for purifying phenyl ethyl malonate, comprising the following steps: dissolving coarse phenyl ethyl malonate into a nonpolar solvent; decoloring by active carbon; filtering; mixing and crystallizing at the temperature of -10 DEG C to -5 DEG C; filtering to obtain a first filter cake; decompressing and recovering the solvent by the first filter cake to obtain colorless oil liquid as a fine product; dissolving the fine product into the nonpolar solvent; stirring and crystallizing at the temperature of -10 DEG C to -5 DEG C; filtering to obtain a second filter cake; decompressing the second cake to recover the solvent; and obtaining colorless transparent liquid as a phenyl ethyl malonate pure product. The purity of the phenyl ethyl malonate is greater than or equal to 99.5 percent, 2-phenyl-2-ethyl malonate impurities are less than 0.1 percent, and the total yield is greater than 90.0 percent.

The invention relates to a method and a kit for detecting metabolites in dried blood spots. The metabolites include malonic acid, methyl malonic acid, ethyl malonic acid, me-citrate and total homocysteine, extraction agents containing internal standards are added into the dried blood spots to perform extraction, vibration incubation and derivatization on the dried blood spots, and the malonic acid, the methyl malonic acid, the ethyl malonic acid, the me-citrate and the total homocysteine in treated dried blood spot samples are detected by a liquid chromatography-tandem mass spectrometry method. The concentration of the malonic acid, the methyl malonic acid, the ethyl malonic acid, the me-citrate and the total homocysteine in the filter paper dried blood spot samples can be measured, the method and the kit are used for auxiliary diagnosis of methylmalonic acidemia, methylmalonic acidemia combined homocystinemia, homocystinemia and propionic acidemia, diagnosis efficiency is high, and diagnosis time can be shortened.

The invention discloses a method for synthesizing remote fluorinated aryl olefin, and belongs to the field of organic chemistry. The preparation method comprises the following steps: carrying out a reaction by taking 2-allyl-2-phenethyl diethyl malonate and a derivative thereof as raw materials in the presence of a phosphorus ligand, an inorganic alkali and an organic solvent to obtain the fluorinated olefin compound triethyl (E)-1,1-difluoro-7-phenylhept-6-ene-1,5,5-tricarboxylic acid. According to the method, the method can be completed in one step under the catalysis of palladium, difluoroalkylation is achieved while olefin isomerization is conducted, and a direct and effective way is provided for synthesis of the compound.

The invention relates to a synthetic method of 2,2-bis (trifluoroethyl) propanol and mainly solves the technical problem that the existing synthetic method is lack of industrialization prospect. The method includes subjecting dibenzyl ester malonate and trifluoroethyl triflate to a step-by-step reaction in the presence of an alkalization agent to obtain 2,2-bis (trifluoroethyl) dibenzyl ester malonate 2; reducing the composition 2 through lithium aluminum hydride to obtain 2,2-bis (trifluoroethyl)-1,3-propylene glycol; and using tosyl to protect one hydroxyl and then using sodium borohydride for reduction to obtain the 2,2-bis (trifluoroethyl) propanol. The 2,2-bis (trifluoroethyl) propanol can be prepared quickly and conveniently through the method.

A highly active supported chromium catalyst composition for ethylene and other olefins polymerization and also for ethylene copolymerization with efficient incorporation of comonomer, produces polymers with superior spherical morphology, improved bulk density and almost 0% fines. The catalyst composition component includes at least one chromium compound, mainly chromium acetylacetonate, or chromium hexaflouroacetonylacetonate, or chromium diethylmalonate. One magnesium compound, or aluminum compound, metal alkoxy compound and defined polymer particles mainly chloromethylated cross linked styrene-DVB copolymer or polyvinylchloride. The catalyst composition, when used in conjunction with an organoaluminum compound or a mixture of organoaluminum compounds, can be used for olefin polymerization to produce medium or high density polyethylene and copolymers of ethylene with alpha-olefins having about 3 to 18 carbon atoms.

The present disclosure teaches systems and methods of diagnosing and treating the distinct biologic components that contribute to chronic pain symptoms experienced by patients. A biologic sample is obtained from a patient. Levels of two or more biomarkers (e.g., methylmalonic acid, homocysteine, xanthurenic acid, 3-hydroxypropyl mercapturic acid (3-HPMA), pyroglutamate, hydroxymethylglutarate (HMG), quinolinic acid, kynurenine acid, 5-hydroxyindoleacetate (5-HIAA), vanilmandelate (VMA), and ethylmalonic acid) in the biologic sample are experimentally determined. Based on the existence of abnormal results in one or more biomarkers the patient is diagnosed as having the nerve health, oxidative stress, chronic inflammation pain, and/or neurotransmitter pain components to their chronic pain. Based on the resulting diagnoses administration of certain support compounds is directed. The patient may retest after a sufficient period of time to observe any longitudinal differences in the test results and adjust treatment accordingly. Further, the biomarker data gathered from pain-neutral and chronic pain patients (particularly those using opioid therapies) will be used to characterize biochemistries going forward.

The invention relates to platinum (II) complexes having antitumor activities, and preparation methods thereof. The platinum (II) complexes treat an ammonia molecule as an accompanying group, and treat methylmalonic acid and ethylmalonic acid as leaving groups respectively. The series of the above compounds have the antitumor activities. The structure of the compounds is shown in the specification.

The invention relates to a preparation method of (2R, 3R)-3-methyl-3-phenylalanine. The technical problems that an existing preparation method is long in route, expensive in used reagent, incapable of achieving large-scale production and the like are mainly solved. According to the technical scheme, the preparation method of the (2R, 3R)-3-methyl-3-phenylalanine comprises the following steps: condensing 2-acetamidomalonic acid diethyl ester and 1-bromoethyl benzene under the action of alkali to obtain 2-acetamido-2-(1-phenylethyl) malonic acid diethyl ester; heating and hydrolyzing in concentrated hydrochloric acid, concentrating and crystallizing to obtain erythro 3-methyl-3-phenylalanine; then performing acylation to obtain the erythro 2-acetamido-3-methyl 3-phenylalanine; splitting under the action of acetamido transferase, and obtaining (2R, 3R)-2-acetamido-3-methyl 3-phenylalanine; and finally, heating and hydrolyzing by using hydrochloric acid to obtain the product (2R, 3R)-3-methyl-3-phenylalanine (hydrochloride).

A process for preparation of diethyl 2-aetamido-2-(4-octyl phenyl)ethyl malonate (III), a key intermediate of fingolimod hydrochloride comprising reaction of 2-(4-octylphenyl)ethyl iodide (IV) with diethyl acetamido malonate in presence of a base and an iodinating agent and in an organic solvent. The compound of formula (III) thus obtained provided fingolimod hydrochloride (Ia) having associated impurities below the regulatory limits.

The present invention relates to a preparation method of a drug pentobarbital (1) for sedation, hypnosis, pre-anesthesia administration and anti-convulsion, and provides a new preparation process for preparing high-purity pentobarbital (I) from diethyl ethylmalonate, wherein the process comprises three steps: A, bromination; B, alkylation; and C, cyclization, acidification, and purification. According to the present invention, the method has advantages of simple operation, short production cycle, low energy consumption, mother liquor circulation, less three-waste, stable process, good product quality, high product purity, isomer impurity content of less than 0.1%, high yield and low production cost, and is suitable for industrial production.

The invention discloses a method for preparing vinpocetine intermediate gamma-hydroxypropyl-ethylmalonic acid, and belongs to the chemical industry synthesis field. The preparation method comprises the following steps: 1, adding sodium hydride into an organic solvent, adding 2-ethyl diethylmalonate and 1-bromo-3-chloropropane, extracting by using ethyl acetate, and carrying out reduced pressure concentration of a solvent to obtain gamma-chloropropyl-ethyl diethylmalonate; and 2, adding gamma-chloropropyl-ethyl diethylmalonate to an ethanol-water solvent of sodium hydroxide, refluxing, adding a proper amount of water, adjusting the pH value to 1 by using concentrated hydrochloric acid, crystallizing, and carrying out pumping filtration to obtain a white solid gamma-hydroxypropyl-ethylmalonic acid, wherein a molar ratio of 2-ethyl diethylmalonate to 1-bromo-3-chloropropane to sodium hydride in step 1 is 1:1-1.2:1-1.3; and a reaction temperature in the step 1 is 10-40DEG C, and a reaction time of 1-bromo-3-chloropropane, 2-ethyl diethylmalonate and 1-bromo-3-chloropropane is 8-15h. The intermediate is gamma-hydroxypropyl-ethylmalonic acid, and the preparation method has the advantages of cheap and easily available raw materials, low cost, short reaction steps, simple operation, good product quality, and benefit for protecting the green resource.

The invention belongs to the technical field of drug synthesis and particularly relates to a method for preparing 5-ethyl-5-(1-methylbutyl)malonylurea. A mixture which is obtained after ethyl-propanedioic acid diethyl ester (III) reacts with an alcohol solution of sodium ethoxide reacts with methanesulfonic acid (2-pentyl) ester under the condition that toluene exists, and an ethyl-(1-methylbutyl) diethyl malonate compound (II) is obtained through rectification; the compound (II) reacts with urea under the condition that a methanol solution of sodium methoxide exists, and a fine 5-ethyl-5-(1-methylbutyl)malonylurea (I) product is obtained through hydrochloric acid acidizing and re-crystallization. The technology is stable, reaction conditions are moderate, control is easy, the obtained product is high in purity and high in yield, the conversion rate nearly reaches 100%, post-processing is easy and convenient, energy consumption is low, three wastes are few, mother liquor can be continuously used, production cost is low, and the method is suitable for industrial production.